Recently, targeted therapies against oncogenic receptor tyrosine kinases (RTKs), e.g., FGFR, HER1, HER2, HER3, or MET, have been tested in patients with gastric cancer [8]. This evidence concerns the gene ERBB3 and gastric cancer.